9,684 Shares in Grail, Inc. (NASDAQ:GRAL) Acquired by Decheng Capital LLC

Decheng Capital LLC acquired a new stake in Grail, Inc. (NASDAQ:GRAL - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 9,684 shares of the company's stock, valued at approximately $173,000. Grail accounts for approximately 0.0% of Decheng Capital LLC's investment portfolio, making the stock its 27th biggest holding.

Several other hedge funds also recently added to or reduced their stakes in GRAL. Crcm LP purchased a new stake in shares of Grail during the fourth quarter worth about $65,061,000. Primecap Management Co. CA purchased a new stake in shares of Grail during the fourth quarter worth about $37,118,000. Vanguard Group Inc. acquired a new position in Grail in the fourth quarter worth about $25,902,000. Arbiter Partners Capital Management LLC acquired a new position in Grail in the fourth quarter worth about $14,827,000. Finally, Geode Capital Management LLC acquired a new position in Grail in the fourth quarter worth about $7,920,000.

Analyst Ratings Changes

A number of equities analysts recently commented on GRAL shares. Morgan Stanley lifted their price target on Grail from $16.00 to $20.00 and gave the stock an "equal weight" rating in a research note on Tuesday, March 18th. Canaccord Genuity Group started coverage on Grail in a research note on Monday, April 21st. They issued a "buy" rating and a $32.00 price target for the company.

Grail Stock Down 0.2 %

NASDAQ:GRAL traded down $0.09 during mid-day trading on Tuesday, reaching $36.81. The stock had a trading volume of 1,515,161 shares, compared to its average volume of 1,224,964. The stock's 50 day simple moving average is $30.83 and its two-hundred day simple moving average is $24.58. Grail, Inc. has a 1-year low of $12.33 and a 1-year high of $63.99.

Grail (NASDAQ:GRAL - Get Free Report) last issued its earnings results on Thursday, February 20th. The company reported ($1.86) EPS for the quarter, beating analysts' consensus estimates of ($4.41) by $2.55. The company had revenue of $38.25 million during the quarter, compared to analyst estimates of $35.33 million. Sell-side analysts predict that Grail, Inc. will post -15.15 EPS for the current fiscal year.

Insider Buying and Selling at Grail

In other Grail news, CEO Robert P. Ragusa sold 7,625 shares of Grail stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $31.21, for a total value of $237,976.25. Following the completion of the transaction, the chief executive officer now directly owns 828,662 shares in the company, valued at $25,862,541.02. The trade was a 0.91 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, President Joshua J. Ofman sold 2,109 shares of Grail stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $31.20, for a total value of $65,800.80. Following the sale, the president now directly owns 559,673 shares in the company, valued at approximately $17,461,797.60. This trade represents a 0.38 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 11,550 shares of company stock worth $360,436 over the last ninety days.

Grail Company Profile

GRAIL, Inc is a healthcare company. It engages in the development of a technology for early detection of cancer. The company was founded by Jeffrey T. Huber, William H. Rastetter, and Mostafa Ronaghi on September 11, 2015 and is headquartered in Menlo Park, CA.